Shire (SHPGY) Files Suits to Protect VYVANSE Patents
Tweet
Share
E-mailGet Alerts SHPGY Hot Sheet
Join SI Premium – FREE
Shire plc (Nasdaq: SHPGY) has filed lawsuits in the U.S. District Court for the District of New Jersey against each of Amneal Pharmaceuticals, LLC and Sandoz, Inc., for infringement of certain of Shire's VYVANSE patents.
The lawsuits were initiated in response to Abbreviated New Drug Applications filed by Amneal and Sandoz seeking FDA approval to market and sell generic versions of all currently approved doses of VYVANSE.
The lawsuits were initiated in response to Abbreviated New Drug Applications filed by Amneal and Sandoz seeking FDA approval to market and sell generic versions of all currently approved doses of VYVANSE.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- F&M Bank (FMAO) Appoints Mark Hutchinson as Treasurer
- Whirlpool (WHR) to cut 1,000 jobs - CFO Jim Peters
Create E-mail Alert Related Categories
Corporate News, FDA, LitigationSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
